These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35461372)

  • 1. Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction.
    Vadla GP; Daghat B; Patterson N; Ahmad V; Perez G; Garcia A; Manjunath Y; Kaifi JT; Li G; Chabu CY
    Sci Rep; 2022 Apr; 12(1):6693. PubMed ID: 35461372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
    Li XF; Shen WZ; Jin X; Ren P; Zhang J
    Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIV Infection Regulates Compartmentalization of Circulating Blood Plasma miRNAs within Extracellular Vesicles (EVs) and Extracellular Condensates (ECs) and Decreases EV-Associated miRNA-128.
    Kopcho S; McDew-White M; Naushad W; Mohan M; Okeoma CM
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992331
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
    Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
    Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K
    Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients.
    Janpipatkul K; Trachu N; Watcharenwong P; Panvongsa W; Worakitchanon W; Metheetrairut C; Oranratnachai S; Reungwetwattana T; Chairoungdua A
    Cancer Biomark; 2021; 31(3):281-294. PubMed ID: 33896827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
    Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI.
    Ma Y; Pan X; Xu P; Mi Y; Wang W; Wu X; He Q; Liu X; Tang W; An HX
    Oncotarget; 2017 Oct; 8(51):88529-88536. PubMed ID: 29179454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells.
    Liu S; Jiang Z; Xiao P; Li X; Chen Y; Tang H; Chai Y; Liu Y; Zhu Z; Xie Q; He W; Ma Y; Jin L; Feng W
    Cancer Sci; 2022 Jan; 113(1):79-90. PubMed ID: 34706132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC).
    Abdipourbozorgbaghi M; Vancura A; Radpour R; Haefliger S
    Br J Cancer; 2024 Nov; 131(8):1350-1362. PubMed ID: 39215192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L; Fan J; Qian R; Luo P; Zhang J
    Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.
    Genova C; Marconi S; Chiorino G; Guana F; Ostano P; Santamaria S; Rossi G; Vanni I; Longo L; Tagliamento M; Zullo L; Dal Bello MG; Dellepiane C; Alama A; Rijavec E; Ludovini V; Barletta G; Passiglia F; Metro G; Baglivo S; Chiari R; Rivoltini L; Biello F; Baraibar I; Gil-Bazo I; Novello S; Grossi F; Coco S
    Clin Exp Med; 2024 Aug; 24(1):182. PubMed ID: 39105937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
    Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
    Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
    Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
    Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib.
    Kuo CS; Huang CH; Liu CY; Pavlidis S; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Target Oncol; 2019 Aug; 14(4):433-440. PubMed ID: 31346928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.
    Zhang W; Zhang Q; Che L; Xie Z; Cai X; Gong L; Li Z; Liu D; Liu S
    BMC Cancer; 2022 Mar; 22(1):299. PubMed ID: 35313857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.